#GISeries: Here we🗣️about the @US_FDA approval of #Fruquintinib from #FRESCO2 & how it fits in our Rx paradigm w/@adasarimd Full Int: - targetedonc.com/pivotal-practi… - oncbrothers.com/JC-FRESCO2 - Also on the “Oncology Brothers” podcast #OncTwitter #MedTwitter @TargetedOnc #crcsm
@OncBrothers @US_FDA @adasarimd @TargetedOnc @CathyEngMD @BijoyTelivala @RenoHemonc @GIcancerDoc @smitha42 @DrR_DUNNE @KristenCiombor @ARosen380 @Dr_M_Tejani @pashtoonkasi 3rd line mCRC is a real unmet need. Do you think an OS 🔼 of 2.6mo and PFS 🔼 of 1.9mo (barely the time between first and second CT scans) is enough for our pts? ( it is certainly enough for the FDA to grant the company to rake in exorbitant profits).
@EinatShacham @US_FDA @adasarimd @TargetedOnc @CathyEngMD @BijoyTelivala @RenoHemonc @GIcancerDoc @smitha42 @DrR_DUNNE @KristenCiombor @ARosen380 @Dr_M_Tejani @pashtoonkasi Completely agree! This is not a home run by any means and we absolutely need to do better. But this seems to be a step in the right direction. With Rego barely used, this gives us another potential oral option. But yes, ≥3L remains a big unmet need. #gism #crcsm #OncTwitter